Interleukin 2 receptor antagonists for liver transplant recipients: A systematic review and meta-analysis of controlled studies
Open accessAbstract
Interleukin 2 receptor antagonists (IL-2Ra) are frequently used as induction therapy in liver transplant recipients to decrease the risk of acute rejection while allowing the reduction of concomitant immunosuppression. We conducted a systematic review of prospective, controlled studies to test the hypothesis that the use of IL-2Ra is associated with a decrease in acute rejection and/or a decrease in the side effects of concomitant medication. We performed a search of all major databases and secondary sources from inception to December 2010. Random effects models were used to assess the incidence of acute rejection, graft loss, patient death, and adverse side effects, with or without IL-2Ra. Subgroup analysis and meta-regression were used to explore differences in effect and sources of heterogeneity. Eighteen studies (13 randomized and 5 nonrandomized) met the inclusion and exclusion criteria. Acute rejection at 12 months or later favored the use of IL-2Ra (relative risk [RR] 0.83; 95% confidence interval [CI] 0.76-0.94) and steroid-resistant rejection was also less frequent in patients receiving IL-2Ra (RR 0.66; CI 0.48-0.91). Graft loss and patient death did not differ significantly between treatments. Patients who received IL-2Ra in addition to reduced or delayed calcineurin inhibitors had better renal function (mean difference of estimated glomerular filtration rate: 6.29 mL/min; CI 1.66-10.91) and a lower incidence of renal dysfunction (RR 0.46; CI 0.27-0.78). The use of IL-2Ra was also associated with a lower incidence of posttransplant diabetes mellitus, whereas the incidence of other adverse events was similar. Conclusion: The use of IL-2Ra is associated with a lower incidence of acute rejection after transplantation. Concomitant immunosuppression can be reduced, avoiding long-term side effects of immunosuppression. (Hepatology 2011;).
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Antithymocyte globulin and interleukin 2 receptor antagonists are linked to lower posttransplant diabetes risk.
“Other immunosuppressive therapy associated with a lower risk of PTDM include antithymocyte globulin and Interleukin 2 receptor antagonists.1583,1589,1596,1597”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1583]
Among immunosuppressive agents, belatacept appears least diabetogenic and tacrolimus carries the highest posttransplant diabetes risk.
“Of the various immunosuppressive agents, belatacept1582,1583 appears to be the least diabetogenic and tacrolimus having the highest risk for PTDM.1584–1590”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1583]
The Complications and Side Effects of Immunosuppression section reports lower PTDM incidence with IL-2 receptor antagonist regimens, particularly with steroid avoidance. It does not rank tacrolimus against other agents for PTDM risk. The belatacept clause has separate citations in the citing sentence; searches for a tacrolimus–cyclosporine diabetes comparison and diabetogenicity did not establish the claim from this paper. (LLM, conf=0.76)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823 · see citing works
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042 · see citing works
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139 · see citing works
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722 · see citing works
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859 · see citing works
A Coefficient of Agreement for Nominal Scales
Cohen, J. (1960) · Educational and Psychological Measurement · doi:10.1177/001316446002000104 · Cited by 42,398 · see citing works
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048 · see citing works
Stroup, D. F. (2000) · JAMA · doi:10.1001/jama.283.15.2008 · Cited by 20,623 · see citing works
Conducting Meta-Analyses in <i>R</i> with the <b>metafor</b> Package
Viechtbauer, W. (2010) · Journal of Statistical Software · doi:10.18637/jss.v036.i03 · Cited by 20,464 · see citing works
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (2008) · The Nephron journals/Nephron journals · doi:10.1159/000180580 · Cited by 15,291 · see citing works
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079 · see citing works
Duval, S., & Tweedie, R. (2000) · Biometrics · doi:10.1111/j.0006-341x.2000.00455.x · Cited by 14,099 · see citing works
Deeks, J. J., Altman, D. G., & Bradburn, M. J. (2001) · Systematic Reviews in Health Care · doi:10.1002/9780470693926.ch15 · Cited by 2,163 · see citing works
Interleukin-2–Receptor Blockade with Daclizumab to Prevent Acute Rejection in Renal Transplantation
Vincenti, F., Kirkman, R. L., Light, S. E., Bumgardner, G. L., Pescovitz, M. D., Halloran, P. F., Neylan, J. F., Wilkinson, A. H., Ekberg, H., Gaston, R. S., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801153380304 · Cited by 861 · see citing works
Nashan, B., Moore, R. H., Amlot, P. L., Schmidt, A.-G., Abeywickrama, K. H., & Soulillou, J. (1997) · The Lancet · doi:10.1016/s0140-6736(97)09278-7 · Cited by 746 · see citing works
A humanized antibody that binds to the interleukin 2 receptor.
Queen, C., Schneider, W. P., Selick, H. E., Payne, P. W., Landolfi, N. F., Duncan, J. F., Avdalovic, N. M., Levitt, M., Junghans, R. P., & Waldmann, T. A. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.24.10029 · Cited by 627 · see citing works
Confidence intervals for the amount of heterogeneity in meta‐analysis
Viechtbauer, W. (2006) · Statistics in Medicine · doi:10.1002/sim.2514 · Cited by 399 · see citing works
Neuberger, J., Mamelok, R. D., Neuhaus, P., Pirenne, J., Samuel, D., Isoniemi, H., Rostaing, L. P. E., Rimola, A., Marshall, S. F., & Mayer, A. (2008) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2008.02493.x · Cited by 288 · see citing works
McAlister, V. C., Haddad, E. H., Renouf, E. M., Malthaner, R. A., Kjaer, M., & Gluud, L. L. (2006) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2006.01360.x · Cited by 263 · see citing works
Webster, A. C., Playford, E. G., Higgins, G. Y., Chapman, J. R., & Craig, J. C. (2004) · Transplantation · doi:10.1097/01.tp.0000109643.32659.c4 · Cited by 225 · see citing works
Neuhaus, P., Clavien, P., Kittur, D., Salizzoni, M., Rimola, A., Abeywickrama, K., Ortmann, E., Chodoff, L., Hall, M., Korn, A., et al. (2002) · Liver Transplantation · doi:10.1053/jlts.2002.30302 · Cited by 184 · see citing works
Cai, J., & Terasaki, P. I. (2010) · Transplantation · doi:10.1097/tp.0b013e3181fecfcb · Cited by 166 · see citing works
Yoshida, E. M., Marotta, P. J., Greig, P. D., Kneteman, N. M., Marleau, D., Cantarovich, M., Peltekian, K. M., Lilly, L., Scudamore, C. H., Bain, V. G., et al. (2005) · Liver Transplantation · doi:10.1002/lt.20490 · Cited by 147 · see citing works
Calcineurin-inhibitor minimization protocols in heart transplantation
Zuckermann, A. O., & Aliabadi, A. Z. (2008) · Transplant International · doi:10.1111/j.1432-2277.2008.00771.x · Cited by 131 · see citing works
Klintmalm, G. B. G., Washburn, W. K., Rudich, S. M., Heffron, T. G., Teperman, L. W., Fasola, C. G., Eckhoff, D. E., Netto, G. J., & Katz, E. (2007) · Liver Transplantation · doi:10.1002/lt.21182 · Cited by 128 · see citing works
Boillot, O., Mayer, D. A., Boudjéma, K., Salizzoni, M., Gridelli, B. G., Filipponi, F., Trunečka, P., Krawczyk, M., Clavien, P., Ducerf, C., et al. (2005) · Liver Transplantation · doi:10.1002/lt.20307 · Cited by 111 · see citing works
Calcineurin inhibitor minimization protocols in liver transplantation
Farkas, S. A., Schnitzbauer, A. A., Kirchner, G. I., Obed, A., Banas, B., & Schlitt, H. J. (2008) · Transplant International · doi:10.1111/j.1432-2277.2008.00796.x · Cited by 90 · see citing works
Self-citationAsrani, S. K., Leise, M. D., West, C. P., Murad, H. M., Pedersen, R. A., Erwin, P. J., Tian, J., Wiesner, R. H., & Kim, W. R. (2010) · Hepatology · doi:10.1002/hep.23835 · Cited by 85 · see citing works
Kato, T., Gaynor, J. J., Yoshida, H., Montalvano, M., Takahashi, H., Pyrsopoulos, N., Nishida, S., Moon, J., Selvaggi, G., Levi, D., et al. (2007) · Transplantation · doi:10.1097/01.tp.0000282914.20578.7b · Cited by 77 · see citing works
Washburn, K., Speeg, K. V., Esterl, R. M., Cigarroa, F. G., Pollack, M. S., Tourtellot, C., Maxwell, P., & Halff, G. A. (2001) · Transplantation · doi:10.1097/00007890-200111270-00018 · Cited by 73 · see citing works
The Renal-Sparing Efficacy of Basiliximab in Adult Living Donor Liver Transplantation
Lin, C., Chuang, F., Lee, C.-H., Wang, C., Chen, Y., Liu, Y., Jawan, B., & Chen, C. (2005) · Liver Transplantation · doi:10.1002/lt.20520 · Cited by 67 · see citing works
CLINICAL AND SUBCLINICAL ACUTE REJECTION EARLY AFTER LIVER TRANSPLANTATION
Tippner, C., Nashan, B., Hoshino, K., Schmidt-Sandte, E., Akimaru, K., ker, K. H. W. B., & Schlitt, H. J. (2001) · Transplantation · doi:10.1097/00007890-200109270-00024 · Cited by 64 · see citing works
Calmus, Y., Kamar, N., Gugenheim, J., Duvoux, C., Ducerf, C., Wolf, P., Samuel, D., Vanlemmens, C., Neau‐Cransac, M., Salamé, E., et al. (2010) · Transplantation · doi:10.1097/tp.0b013e3181db8cf0 · Cited by 55 · see citing works
Anti-interleukin-2 receptor antibodies: basiliximab and daclizumab
Pascual, J. (2001) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/16.9.1756 · Cited by 50 · see citing works
Lupo, L., Panzera, P., Tandoi, F., Carbotta, G., Giannelli, G., Santantonio, T. A., Rendina, M. G., Gentile, A., & Memeo, V. (2008) · Transplantation · doi:10.1097/tp.0b013e318186b8a3 · Cited by 49 · see citing works
Humar, A., Crotteau, S., Gruessner, A. C., Kandaswamy, R., Gruessner, R. W. G., Payne, W. K., & Lake, J. R. (2007) · Clinical Transplantation · doi:10.1111/j.1399-0012.2007.00683.x · Cited by 39 · see citing works
Interleukin-2-Receptor Blockade With Daclizumab to Prevent Acute Rejection in Renal Transplantation
Vincenti, F., Kirkman, R. L., Light, S. E., Bumgardner, G. L., Pescovitz, M. D., Halloran, P. F., Neylan, J. F., Wilkinson, A., Ekberg, H., Gaston, R. S., et al. (1999) · The Journal of Urology · doi:10.1016/s0022-5347(01)61859-7 · Cited by 26 · see citing works
Schmeding, M., Sauer, I. M., Kießling, A., Pratschke, J., Neuhaus, R., Neuhaus, P., & Neumann, U. P. (2007) · PubMed · Cited by 24 · see citing works
Daclizumab induction in liver transplant recipients
Heffron, T. G., Smallwood, G. A., de Vera, M. E., Davis, L. P., Martínez, E., & Stieber, A. C. (2001) · Transplantation Proceedings · doi:10.1016/s0041-1345(00)02583-5 · Cited by 23 · see citing works
IL-2 receptor blockers in liver transplantation: initial experience with daclizumab in Chile
Innocenti, F. A., Roberto Humeres, A., Zamboni, M. M., Sanhueza, E., Zapata, R., Hepp, J., & Montserrat Rius, A. (2003) · Transplantation Proceedings · doi:10.1016/j.transproceed.2003.09.021 · Cited by 7 · see citing works
Lu, A., Zheng, S., Wu, J., Liang, T., Wang, W., Shen, Y., Zhang, M., Shi, S., & Wu, Y. (2006) · PubMed · Cited by 5 · see citing works
SIMONE, P. D., Carlis, L. G. D., Filipponi, F., Grazi, G. L., Cuomo, O., Santaniello, W., Sc, M., Valente, U., Salizzoni, M., Bresadola, F., et al. (2007) · Cited by 3 · see citing works
Flagged first, then by citations
2 of the 44 references couldn’t be matched to a known paper.
Research works printed but not linked: 3
- [10]10. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a pro- posal for reporting. Meta-analysis Of Observational Studies in Epide- miology (MOOSE) group. JAMA 2000;283:2008-2012.
- [21]21. Hu A, He X, Zhu X, Ma Y, Wang G, Wang D, et al. Tacrolimus-based steroid minimization in liver transplantation: A single centre experi- ence. Liver Transplant 2010;16:S74.
- [23]23. Yu Y, Luo XJ, Yi B, Liu C, Jiang XQ. Evaluation of immunosuppressive schemes using non-steroid and early steroid withdrawal in patients follow- ing liver transplantation. J Clin Rehab Tissue Eng Res 2010;14:803-806.
Cited by
Sorted by citations
EASL Clinical Practice Guidelines: Liver transplantation
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.10.006 · Cited by 1,082 · see citing works
“No difference was found in patient and graft survival [284].”
BackgroundBlonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507 · see citing works
Bayesian Random-Effects Meta-Analysis Using the <b>bayesmeta</b> <i>R</i> Package
Röver, C. (2020) · Journal of Statistical Software · doi:10.18637/jss.v093.i06 · Cited by 310 · see citing works
Meta‐analysis of few small studies in orphan diseases
Friede, T., Röver, C., Wandel, S., & Neuenschwander, B. E. (2016) · Research Synthesis Methods · doi:10.1002/jrsm.1217 · Cited by 183 · see citing works
Rodríguez‐Perálvarez, M., Germani, G., Darius, T., Lerut, J., Tsochatzis, E. A., & Burroughs, A. K. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2012.04140.x · Cited by 186 · see citing works
Röver, C., Bender, R., Dias, S., Schmid, C. H., Schmidli, H., Sturtz, S., Weber, S., & Friede, T. (2021) · Research Synthesis Methods · doi:10.1002/jrsm.1475 · Cited by 192 · see citing works
“In the data from the closely related meta-analysis by Goralczyk et al.111 the heterogeneity is estimated at 0.12 (0.38).”
MethodInfluentialPresent state of immunosuppressive therapy in liver transplant recipients
Wiesner, R. H., & Fung, J. J. (2011) · Liver Transplantation · doi:10.1002/lt.22410 · Cited by 120 · see citing works
Röver, C., Bender, R., Dias, S., Schmid, C. H., Schmidli, H., Sturtz, S., Weber, S., & Friede, T. (2021) · White Rose Research Online (University of Leeds, The University of Sheffield, University of York) · Cited by 89 · see citing works
Induction immunosuppression in liver transplantation: a review
Turner, A. P., & Knechtle, S. J. (2013) · Transplant International · doi:10.1111/tri.12100 · Cited by 73 · see citing works
New‐onset diabetes after liver transplantation and its impact on complications and patient survival
Lv, C., Zhang, Y., Chen, X., Huang, X., Xue, M., Sun, Q., Wang, T., Liang, J., He, S., Gao, J., et al. (2015) · Journal of Diabetes · doi:10.1111/1753-0407.12275 · Cited by 69 · see citing works
“However, IL-2Ra, a commonly used antibody, may have certain protective effects against NODAT onset.(55,56) In the present study, IL-2Ra administration reduced the risk of NODAT onset, with an OR of 0.”
BackgroundLerut, J. P., Iesari, S., Foguenne, M., & Lai, Q. (2017) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh.2017.09.06 · Cited by 56 · see citing works
“The same can be stated for the use of corticosteroids, anti-lymphocytic sera and anti-interleukin-2 receptor α antibodies (46,58,68-73).”
BackgroundGoralczyk, A. D., Bari, N., Abu-Ajaj, W., Lorf, T., Ramadori, G. P., Friede, T., & Obed, A. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2012.04157.x · Cited by 50 · see citing works
“In the early phase after OLT the use of interleukin2 receptor inhibitors for induction of immunosuppression allows for reduction or delay of CNI without increasing the risk of acute rejection, graft loss, or patient death, but reducing the risk of acute renal dysfunction and improving long-term renal function (8).”
BackgroundSelf-citationThe AKI Prediction Score: a new prediction model for acute kidney injury after liver transplantation
Kalisvaart, M., Schlegel, A. A., Umbro, I., de Haan, J. E., Polak, W. G., IJzermans, J. N. M., Mirza, D. F., Perera, M. T. P. R., Isaac, J., Ferguson, J., et al. (2019) · HPB · doi:10.1016/j.hpb.2019.04.008 · Cited by 46 · see citing works
Recent advances in methodology for clinical trials in small populations: the InSPiRe project
Friede, T., Posch, M., Zohar, S., Alberti, C., Benda, N., Comets, E., Day, S. J., Dmitrienko, A. A., Graf, A. C., Günhan, B. K., et al. (2018) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-018-0919-y · Cited by 46 · see citing works
Update on Immunosuppression in Liver Transplantation
Gurakar, A. O., Tasdogan, B., Şimşek, C., Ma, M., & Saberi, B. (2017) · Euroasian Journal of Hepato-Gastroenterology · doi:10.5005/jp-journals-10018-1301 · Cited by 44 · see citing works
Crins, N. D., Röver, C., Goralczyk, A. D., & Friede, T. (2014) · Pediatric Transplantation · doi:10.1111/petr.12362 · Cited by 42 · see citing works
Self-citationPenninga, L., Wettergren, A., Wilson, C. H., Chan, A., Steinbrüchel, D. A., & Gluud, C. N. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010253.pub2 · Cited by 40 · see citing works
Model averaging for robust extrapolation in evidence synthesis
Röver, C., Wandel, S., & Friede, T. (2018) · Statistics in Medicine · doi:10.1002/sim.7991 · Cited by 39 · see citing works
Bittermann, T., Hubbard, R. A., Lewis, J. D., & Goldberg, D. S. (2019) · American Journal of Transplantation · doi:10.1111/ajt.15513 · Cited by 36 · see citing works
Antibody induction versus corticosteroid induction for liver transplant recipients
Penninga, L., Wettergren, A., Wilson, C. H., Chan, A., Steinbrüchel, D. A., & Gluud, C. N. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010252.pub2 · Cited by 29 · see citing works
Lack of Benefit and Potential Harm of Induction Therapy in Simultaneous Liver‐Kidney Transplants
AbdulRahim, N., Anderson, L., Kotla, S. K., Liu, H., Ariyamuthu, V. K., Ghanta, M., MacConmara, M. P., Tujios, S. R., Mufti, A., Mohan, S., et al. (2018) · Liver Transplantation · doi:10.1002/lt.25390 · Cited by 23 · see citing works
“Time on waiting list, days 69 (17-269) 69 (17-243) 66 (16-232) 0.”
BackgroundImmunomodulating options for liver transplant patients
Zarrinpar, A., & Busuttil, R. W. (2012) · Expert Review of Clinical Immunology · doi:10.1586/eci.12.47 · Cited by 21 · see citing works
Shigeta, T., Sakamoto, S., Uchida, H., Sasaki, K., Hamano, I., Kanazawa, H., Fukuda, A., Kawai, T., Onodera, M., Nakazawa, A., et al. (2014) · Pediatric Transplantation · doi:10.1111/petr.12373 · Cited by 21 · see citing works
“However, basiliximab did not affect the long-term patient or graft survival after LT (15).”
BackgroundHashim, M. S., Alsebaey, A., Ragab, A., Soliman, H., & Waked, I. A. (2018) · Annals of Hepatology · doi:10.5604/01.3001.0012.2246 · Cited by 20 · see citing works
Immunosuppression and Liver Transplantation
Lerut, J. P., & Iesari, S. (2022) · Engineering · doi:10.1016/j.eng.2022.07.007 · Cited by 20 · see citing works
Mouzaki, M., Yap, J. Y. K., Avinashi, V., Babu, A., Fu, A., Deangelis, M., Roestel, K. V., Ghanekar, A., Kamath, B. M., Avitzur, Y., et al. (2013) · Pediatric Transplantation · doi:10.1111/petr.12158 · Cited by 19 · see citing works
“Adults receiving IL-2 receptor antagonists as a means of CNI minimization were found to have improved long-term renal function in a recent meta-analysis (4).”
BackgroundKim, H., Yi, N., Song, E. Y., Lee, K., Lee, K., Lee, H. W., Ahn, H. Y., Yoon, K. C., Hong, S. K., & Suh, K. (2018) · Clinical Transplantation · doi:10.1111/ctr.13244 · Cited by 19 · see citing works
Immunosuppression in liver and intestinal transplantation
Lerut, J. P., & Gondolesi, G. E. (2021) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2021.101767 · Cited by 17 · see citing works
Martin, E. D., Londoño, M., Emamaullee, J. A., Lerut, J. P., Potts, J., Aluvihare, V. R., Spiro, M. D., Raptis, D. A., McCaughan, G. W., & the ERAS4OLT.org Working Group (2022) · Clinical Transplantation · doi:10.1111/ctr.14614 · Cited by 17 · see citing works
Clinical Practice Guidelines for Liver Transplantation in Saudi Arabia
Abaalkhail, F. A., Sebayel, M. I. A., Shagrani, M., O’Hali, W., AlMasri, N., Alalwan, A. M., Al-Ghamdi, M. Y., Al-Bahili, H., Alqahtani, M. S., Alabbad, S. I., et al. (2021) · Saudi Medical Journal · doi:10.15537/smj.2021.42.9.20210126 · Cited by 19 · see citing works
Liver Transplantation for Colorectal Liver Metastases: Current Management and Future Perspectives
Puia-Negulescu, S., Lebossé, F., Mabrut, J., Muller, X., Rossignol, G., Antonini, T., Erard, D., Radenne, S., Guillet, M., Souquet, J.-C., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063093 · Cited by 15 · see citing works
“Additionally introduced in the late 1990s, basiliximab is an anti-CD25 monoclonal antibody that offers decreased rates of acute cellular rejection and preserves renal function [28].”
BackgroundWu, L., Tam, N. L., Deng, R., Wu, C., Chen, P., Wang, D., & He, X. (2014) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2014.04.005 · Cited by 14 · see citing works
Retractedbayesmeta: Bayesian Random-Effects Meta-Analysis and Meta-Regression
Röver, C. (2015) · doi:10.32614/cran.package.bayesmeta · Cited by 14 · see citing works
Sofia, M. A., & Rubin, D. T. (2017) · Digestive Diseases and Sciences · doi:10.1007/s10620-017-4479-0 · Cited by 11 · see citing works
Hibi, T., Nishida, S., Sageshima, J., Levi, D., Ruiz, P., Roth, D., Martin, P. B., Okabayashi, K., Burke, G. W., Ciancio, G., et al. (2014) · Transplant International · doi:10.1111/tri.12303 · Cited by 11 · see citing works
Zhang, Y., Jin, W., & Cai, X. (2016) · Annals of Medicine · doi:10.1080/07853890.2016.1257862 · Cited by 11 · see citing works
Kato, H., Hamada, T., Kuriyama, N., Ito, T., Magawa, S., Azumi, Y., Kishiwada, M., Mizuno, S., Usui, M., Sakurai, H., et al. (2016) · Hepatology Research · doi:10.1111/hepr.12740 · Cited by 10 · see citing works
Choudhury, A. K., Rajaram, R. B., & Sarin, S. K. (2024) · Hepatology International · doi:10.1007/s12072-024-10711-4 · Cited by 9 · see citing works
“Steroids is needed in first 3 months post-LT, but more focus needed for persistent hyperglycemia, elevated blood pressure, infection, and osteoporosis at the sametime [122, 123].”
Pascher, A., Nebrig, M., & Neuhaus, P. (2013) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2013.0167 · Cited by 9 · see citing works
Togashi, J., Sugawara, Y., Akamatsu, N., Tamura, S., Tanaka, T., Kaneko, J., Aoki, T., Sakamoto, Y., Hasegawa, K., & Kokudo, N. (2014) · Transplantation Proceedings · doi:10.1016/j.transproceed.2013.11.075 · Cited by 9 · see citing works
“A recent well-conducted meta-analysis of IL2Ra induction in liver transplant recipients concluded that the use of IL2Ra is associated with a lower incidence of acute rejection, concomitant reduction in immunosuppressive agents, and avoidance of long-term side effects of immunosuppression, especially renal dysfunction…”
MethodPenninga, L., Wettergren, A., Wilson, C. H., Chan, A., Steinbrüchel, D. A., & Gluud, C. N. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010253 · Cited by 8 · see citing works
Wei, Q., Wang, K., Yang, M., Chen, J., Shen, T. H., Song, P., Xie, H., Zhou, L., Zheng, S., & Xu, X. (2018) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clirex.2020.100004 · Cited by 7 · see citing works
Antibody induction versus corticosteroid induction for liver transplant recipients
Penninga, L., Wettergren, A., Wilson, C. H., Chan, A., Steinbrüchel, D. A., & Gluud, C. N. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010252 · Cited by 7 · see citing works
Jung, W.-S., Kuh, J. H., Lim, L., Yoo, H. K., Ju, J.-W., Lee, H., & Kim, W. H. (2023) · Scientific Reports · doi:10.1038/s41598-023-32972-z · Cited by 5 · see citing works
Xue, M., Lv, C., Chen, X., Huang, X., Sun, Q., Wang, T., Liang, J., Zhang, Y., He, S., Gao, J., et al. (2015) · Journal of Diabetes · doi:10.1111/1753-0407.12356 · Cited by 5 · see citing works
Rejection After Transplantation
Parekh, J. R., Ascher, N. L., & Roberts, J. P. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-0268-8.00087-7 · Cited by 5 · see citing works
Immunosuppressive T cell antibody induction therapy for liver transplant recipients
Penninga, L., Wettergren, A., Wilson, C. H., Steinbrüchel, D. A., & Gluud, C. N. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007341.pub2 · Cited by 5 · see citing works
Trasplante hepático en adultos: Estado del arte
Santos, O. M., Marín, J. I., Muñoz, O. G., Mena, Á., Guzmán, C., Hoyos, S. I., Restrepo, J. C., & Correa, G. (2012) · Redalyc (Universidad Autónoma del Estado de México) · Cited by 3 · see citing works
Maki, H., Kaneko, J., Akamatsu, N., Arita, J., Sakamoto, Y., Hasegawa, K., Tanaka, T., Tamura, S., Sugawara, Y., Tsukada, K., et al. (2015) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-015-0621-8 · Cited by 3 · see citing works
“46) [11].”
BackgroundImmunosuppression Post-Liver Transplant
Yataco, M. L., & Keaveny, A. P. (2025) · Clinics in Liver Disease · doi:10.1016/j.cld.2024.12.006 · Cited by 2 · see citing works
Immunosuppressive Biologic Agents
MacConmara, M. P., Nwadei, I., & Kirk, A. D. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-0268-8.00096-8 · Cited by 2 · see citing works
Leighton, J., & Wilson, C. J. N. (2020) · Surgery (Oxford) · doi:10.1016/j.mpsur.2020.04.005 · Cited by 2 · see citing works
Immunology of Liver Transplantation
DePalma, R., Knorr, J. P., & Navarro, V. (2017) · Springer eBooks · doi:10.1007/978-3-319-07209-8_20 · Cited by 2 · see citing works
Medical Management after Liver Transplantation
Dave, S., & Ajmera, V. H. (2019) · Digestive Disease Interventions · doi:10.1055/s-0039-1697652 · Cited by 1 · see citing works
Nayagam, J. S., Tavabie, O. D., Norton, B. C., McMahon, M. J., Ramos, K., Cadden, I. S., Cramp, M., Menon, K. V., Prachalias, A. A., Agarwal, K., et al. (2021) · Journal of Liver Transplantation · doi:10.1016/j.liver.2021.100028 · Cited by 1 · see citing works
“Induction therapy with IL2Ra has been described in LT to allow the delayed introduction of CNI, and patient associated outcomes are excellent [15].”
BackgroundImmunosuppression: Conventions and controversies
Mehta, N. J., & Hirose, R. (2013) · Clinical Liver Disease · doi:10.1002/cld.221 · Cited by 1 · see citing works
Shah, J. A. (2023) · Springer eBooks · doi:10.1007/978-981-19-6045-1_41 · Cited by 1 · see citing works
Immunosuppressive Drugs in Solid Organ Transplantation
Berry, G. J., & Morris, R. E. (2016) · Springer eBooks · doi:10.1007/978-3-319-29683-8_3 · Cited by 1 · see citing works
Immunology of Liver Transplantation
DePalma, R., Knorr, J. P., & Navarro, V. (2015) · Springer eBooks · doi:10.1007/978-3-319-05543-5_20-1 · Cited by 1 · see citing works
Figueiredo, R., & Wilson, C. H. (2017) · Surgery (Oxford) · doi:10.1016/j.mpsur.2017.04.011 · Cited by 1 · see citing works
Immunology of Liver Transplantation
DePalma, R., Knorr, J. P., & Navarro, V. (2016) · Springer eBooks · doi:10.1007/978-3-319-05543-5_20-2 · Cited by 1 · see citing works
State of the art liver transplantation in adults
Santos, O. M., Marín, J. I., Muñoz, O. G., Mena, Á., Guzmán, C., Hoyos, S. I., Restrepo, J. C., & Correa, G. (2012) · Revista Colombiana de Gastroenterología
HIV/HCV重複感染肝不全に対する肝移植―抗CD25モノクローナル抗体を用いた免疫抑制療法3例の経験―
真木, 治., 金子順一, 赤松延久, 有田淳一, 良弘, 阪., 田村, 純., 潔, 長., 寧彦, 菅., 智大, 田., 野尻, 佳., et al. (2016) · 移植 · doi:10.11386/jst.51.2-3_211
Post-liver transplantation immonusuppression: main principles and modern implementation
Yesmembetov, K., Kaliaskarova, K., & Spatayev, Z. (2018) · Journal of Clinical Medicine of Kazakhstan · doi:10.23950/1812-2892-jcmk-00340
Wang, D., Xiong, L., Wang, Y., Weng, J., & Gao, L. (2020) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2020.06.012
RetractedTreatment of steroid-resistant acute rejection after living donor liver transplantation
Lee, T. B., Ko, H. J., Shim, J. R., Choi, B. H., Yang, K., & Ryu, J. H. (2021) · Annals of Liver Transplantation · doi:10.52604/alt.21.0015
Biological therapies in patients with liver disease: are they really lifesavers?
Vitale, G., Gitto, S., Campani, C., Turco, L., Baldan, A., Marra, F., & Morelli, M. C. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2013799
“Their application in the induction phase reduces rates of renal dysfunction and post-transplant diabetes mellitus by using lower doses of calcineurin inhibitors [166].”
BackgroundImmunosuppressive T cell antibody induction therapy for liver transplant recipients
Penninga, L., Wettergren, A., Wilson, C. H., Steinbrüchel, D. A., & Gluud, C. N. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007341.pub3
Post-liver transplantation immonusuppression: main principles and modern implementation
Yesmembetov, K., Kaliaskarova, K., & Spatayev, Z. (2018) · Journal of Clinical Medicine of Kazakhstan · doi:10.23950/1812-2892-00340
Figueiredo, R., & Wilson, C. J. N. (2014) · Surgery (Oxford) · doi:10.1016/j.mpsur.2014.04.014
Bari, N. (2022) · doi:10.53846/goediss-9558
Self-citationMahendran, B. S., Figueiredo, R., & Wilson, C. H. (2023) · Surgery (Oxford) · doi:10.1016/j.mpsur.2023.07.001
- Authors
- Goralczyk, A. D., Hauke, N., Bari, N., Y. Tsui, T., Lorf, T., & Obed, A.
- Affiliations
- Universitätsmedizin Göttingen (DE)
- Corresponding author
- Goralczyk, Armin D.
- Venue
- Hepatology
- Published
- 2011-08
- Volume
- 54
- Issue
- 2
- Pages
- 541-554
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W1965042497
- Cited by
- 72
- References
- 44
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 3 · 2022: 4 · 2021: 8 · 2020: 3 · 2019: 3 · 2018: 8 · 2017: 5 · 2016: 7 · 2015: 7 · 2014: 8 · 2013: 4 · 2012: 8
- FWCI
- 1.27
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Hepatology (publishedVersion)
- PubMed (publishedVersion)
- GRO (submittedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Organ Transplantation Techniques and Outcomes
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
- Keywords
- interleukin-2 receptor antagonist, liver transplantation, induction therapy, acute rejection, steroid-resistant rejection, graft loss, patient mortality, immunosuppression reduction, calcineurin inhibitors, renal function, post-transplant diabetes mellitus, adverse drug reactions
- MeSH terms
- Acute Disease, Graft Rejection, Humans, Immunosuppression Therapy, Receptors, Interleukin-2, Liver Transplantation, Controlled Clinical Trials as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
